Immuneering (IMRX) Return on Capital Employed (2021 - 2026)
Immuneering (IMRX) posted quarterly Return on Capital Employed of 27.12% for Q1 2026, up 11075.0% year-over-year from N/an in Q1 2025, and down 3.41% quarter-over-quarter from 26.22% in Q4 2025.
Immuneering (IMRX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Immuneering's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 27.12% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 11075.0% year-over-year to 27.12%; the TTM figure through Mar 2026 stood at 27.12% (up 11075.0% YoY), while the FY2025 annual figure was 44.89%, up 4645.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 27.12%, down from 26.22% in the prior quarter.
- The five-year high for Return on Capital Employed was 26.03% in Q1 2022, with the low at 169.14% in Q2 2025.
- The 5-year median for Return on Capital Employed is 49.31% (2023), against an average of 65.46%.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed slumped 8932 bps in 2025, then surged 11075 bps in 2026.
- Immuneering's Return on Capital Employed stood at 43.13% in 2022, then plunged by 35 bps to 58.19% in 2023, then sank by 107 bps to 120.59% in 2024, then jumped by 78 bps to 26.22% in 2025, then retreated by 3 bps to 27.12% in 2026.
- Business Quant data shows IMRX's Return on Capital Employed at 27.12% in Q1 2026, 26.22% in Q4 2025, and 48.99% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | -31.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.68% |
| Mar 31, 2026 | -27.12% |
| Dec 31, 2025 | -26.22% |
| Sep 30, 2025 | -48.99% |
| Jun 30, 2025 | -169.14% |
| Mar 31, 2025 | -137.86% |
| Dec 31, 2024 | -120.59% |
| Sep 30, 2024 | -93.80% |
| Jun 30, 2024 | -79.82% |
| Mar 31, 2024 | -65.54% |
| Dec 31, 2023 | -58.19% |
| Sep 30, 2023 | -49.31% |
| Jun 30, 2023 | -49.95% |
| Mar 31, 2023 | -48.85% |
| Dec 31, 2022 | -43.13% |
| Sep 30, 2022 | -37.42% |
| Jun 30, 2022 | -30.83% |
| Mar 31, 2022 | -26.03% |
| Dec 31, 2021 | -21.21% |
| Sep 30, 2021 | -27.70% |